Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation

Brain Research Bulletin

Volumn 89, Issue 1-2, 2012, Pages 65-70

  Liu, Huiqing ^a   Liu, Xiaoqian ^a   Wei, Xinbing ^a   Chen, Lin ^a   Xiang, Yanxiao ^a   Yi, Fan ^a   Zhang, Xiumei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Angiotensin II type 1 receptor; Cerebral ischemia reperfusion injury; Losartan; Phosphorylated eNOS; PI3K Akt signaling

Indexed keywords

DIMETHYL SULFOXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LOSARTAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SHAM PROCEDURE; TRANSIENT ISCHEMIC ATTACK; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BRAIN ISCHEMIA; LOSARTAN; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 84864547420     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.06.010     Document Type: Article

References (35)

1. Atochin D.N., Wang A., Liu V.W., Critchlow J.D., Dantas A.P., Looft-Wilson R., Murata T., Salomone S., Shin H.K., Ayata C., Moskowitz M.A., Michel T., Sessa W.C., Huang P.L. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. Journal of Clinical Investigation 2007, 117:1961-1967.
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
3. Briones A.M., Alonso M.J., Hernanz R., Miguel M., Salaices M. Alterations of the nitric oxide pathway in cerebral arteries from spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology 2002, 39:378-388.
4. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., Power D.A., Ortiz de Montellano P.R., Kemp B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Letters 1999, 443:285-289.
5. Chen S., Li G., Zhang W., Wang J., Sigmund C.D., Olson J.E., Chen Y. Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2009, 297:R1526-R1531.
6. Dai W.J., Funk A., Herdegen T., Unger T., Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999, 30:2391-2398.
7. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
8. Engelhorn T., Goerike S., Doerfler A., Okorn C., Forsting M., Heusch G., Schulz R. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. Journal of Cerebral Blood Flow and Metabolism 2004, 24:467-474.
9. Feil R., Lohmann S.M., de Jonge H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circulation Research 2003, 93:907-916.
10. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
11. Guan W., Somanath P.R., Kozak A., Goc A., El-Remessy A.B., Ergul A., Johnson M.H., Alhusban A., Soliman S., Fagan S.C. Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS One 2011, 6:e24551.
12. Haynes M.P., Sinha D., Russell K.S., Collinge M., Fulton D., Morales-Ruiz M., Sessa W.C., Bender J.R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circulation Research 2000, 87:677-682.
13. Inaba S., Iwai M., Tomono Y., Senba I., Furuno M., Kanno H., Okayama H., Mogi M., Higaki J., Horiuchi M. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 2009, 40:597-603.
14. Ito T., Yamakawa H., Bregonzio C., Terrón J.A., Falcón-Neri A., Saavedra J.M. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002, 33:2297-2303.
15. Kagiyama T., Kagiyama S., Phillips M.I. Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regulatory Peptides 2003, 110:241-247.
16. Lindholm L.H., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
17. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension 2003, 21:875-886.
18. 1 receptor/nuclear factor-kappaB pathway in brain microvascular endothelial cells. Life Sciences 2006, 78:1293-11298.
19. Liu H., Kitazato K.T., Uno M., Yagi K., Kanematsu Y., Tamura T., Tada Y., Kinouchi T., Nagahiro S. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in vivo and in vitro studies. Journal of Hypertension 2008, 26:1435-1445.
20. Lu Q., Zhu Y., Wong P. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005, 16:1963-1967.
21. Maeda K., Hata R., Bader M., Walther T., Hossmann K.A. Larger anastomoses in angiotensinogen-knockout mice attenuate early metabolic disturbances after middle cerebral artery occlusion. Journal of Cerebral Blood Flow and Metabolism 1999, 19:1092-1098.
22. Michell B.J., Chen Z., Tiganis T., Stapleton D., Katsis F., Power D.A., Sim A.T., Kemp B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. Journal of Biological Chemistry 2001, 276:17625-17628.
23. Moro M.A., Cárdenas A., Hurtado O., Leza J.C., Lizasoain I. Role of nitric oxide after brain ischaemia. Cell Calcium 2004, 36:265-275.
24. Nishimura Y., Ito T., Saaveedra J.M. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000, 31:2478-2486.
25. Noshita N., Sugawara T., Lewen A., Hayashi T., Chan P.H. Copper-zinc superoxide dismutase affects Akt activation after transient focal cerebral ischemia in mice. Stroke 2003, 34:1513-1518.
26. Oyama N., Yagita Y., Sasaki T., Omura-Matsuoka E., Terasaki Y., Sugiyama Y., Sakoda S., Kitagawa K. An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats. Journal of Neuroscience Research 2010, 88:2889-2898.
27. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circulation Research 2005, 97:1232-1235.
28. Schrader J., Lüders S., Kulschewski A., Berger J., Zidek W., Treib J., Einhäupl K., Diener H.C., Dominiak P. The evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003, 34:1699-1703.
29. Su K.H., Tsai J.Y., Kou Y.R., Chiang A.N., Hsiao S.H., Wu Y.L., Hou H.H., Pan C.C., Shyue S.K., Lee T.S. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling. Cardiovascular Research 2009, 82:468-475.
30. Toda N., Ayajiki K., Okamura T. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacological Reviews 2009, 61:62-97.
31. Walther T., Olah L., Harms C., Maul B., Bader M., Hortnagl H., Schultheiss H.P., Mies G. Ischemic injury in experimental stroke depends on angiotensin II. FASEB Journal 2002, 16:169-176.
32. Watanabe T., Suzuki J., Yamawaki H., Sharma V.K., Sheu S.S., Berk B.C. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005, 112:1798-1805.
33. Wei X., Liu H., Sun X., Fu F., Zhang X., Wang J., An J., Ding H. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neuroscience Letters 2005, 386:58-62.
34. 1 receptor inhibition. Journal of Cerebral Blood Flow and Metabolism 2003, 23:371-380.
35. Yoshitomi H., Xu Q., Gao M., Yamori Y. Phosphorylated endothelial NOS Ser1177 via the PI3K/Akt pathway is depressed in the brain of stroke-prone spontaneously hypertensive rat. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 2011, 20:406-412.